Prostate Cancer News and Research

Latest Prostate Cancer News and Research

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

State regulators and the Massachusetts nursing home industry are launching a campaign today to reduce the inappropriate use of antipsychotic medications for residents with dementia.

19 Nov 2010

Medicare committee recommends expensive drug for some prostate-cancer patients

A new treatment for prostate cancer called Provenge won a vote of confidence from a Medicare coverage advisory committee Wednesday, suggesting the federal program is likely to pay for the $93,000-per-patient medicine.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Women prefer diet advice from women: Study

A new study shows that women do not pay heed to diet advice from men. The study conducted by the Australian National University (ANU) suggests women are more inclined to listen and change their behaviour if the speaker is also female.

18 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.

17 Nov 2010

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

Protox decreases third quarter net and comprehensive loss to $1.6 million

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today released financial results for the third quarter, ended September 30, 2010.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

Medicare committee recommends expensive drug for some prostate-cancer patients

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Women prefer diet advice from women: Study

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Risk reduction of 20 ailments with regular exercise: Review

HUPTI's first group of patients complete prostate cancer treatment

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Protox decreases third quarter net and comprehensive loss to $1.6 million

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in